That’s the question at the heart of two perspectives published this week in Circulation: Cardiovascular Quality and Outcomes, with Rasha Al-Lamee, MBBS, PhD, and Christopher Rajkumar, MBBS (Imperial ...

PHILADELPHIA, PA—More than 6 years since the placebo-controlled ORBITA trial set the interventional cardiology galaxy whirling, ORBITA-2, attempting to isolate the treatment effects of PCI alone, ...

NEW ORLEANS — Addressing a persistent controversy, a tightly blinded trial has confirmed a significant reduction of angina for patients with a chronic total occlusion (CTO) when treated with a ...

Randomised, double-blind, placebo-controlled, multicentre ORBITA-2 trial. 301 participants with stable angina and evidence of ischaemia had antianginal medications withheld for 2 weeks. They were ...

The ORBITA- 2 study found that stents improved chest pain, exercise capacity and quality of life compared to a placebo procedure among patients, with stable chest pain, taking little or no chest pain ...

PHILADELPHIA -- The symptoms of stable angina can be eased by percutaneous coronary intervention (PCI) alone in the absence of antianginal medications, the randomized ORBITA-2 trial showed. Compared ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. PCI improved angina symptoms at 12 weeks vs. a sham ...

MISSISSAUGA, ON, May 4, 2021 /CNW/ - KYE Pharmaceuticals Inc. ("KYE"), a private company headquartered in Mississauga, Ontario focused on bringing medicines that fulfill clinically significant unmet ...